TY - JUR A2 - PELTEKIAN，KEVORK M. AU - 朱朱，东美AU - 谢，景奥烨，春艳，春谦，梅云奥薛，元PY - 2020 DA - 2020/12 /18 TI - 肝细胞癌的风险患者患者与HBV相关的失代偿性肝硬化和长期抗病毒治疗SP - 8871024 VL - 2020 AB - 背景。本研究旨在评估乙型肝炎病毒（HBV）相关DC患者HCC开发的危险因素，涉及长期抗病毒治疗。 方法。收集了308例HBV相关的DC患者和长期抗病毒治疗的数据，并回顾性审查。COX回归分析用于分析HCC开发的独立危险因素。 结果。分析了来自129名明确记录患者的数据。中位后续时间为5年（范围，1至8年）。在随访结束时，41名（31.8％）患者开发了HCC，从DC诊断到HCC接受抗病毒治疗的时间为4.4岁（范围，1 - 7年）。HCC的发病率高于女性（11/51,21.6％）的男性（30/78,38.5％）（ P.  = 0.04). Patients who developed HCC were significantly older than those who did not develop HCC ( P.  < 0.01). The incidence of HCC in patients receiving nucleoside analogues, nucleotide analogues, and combination therapy was 34.7%, 38.1%, and 33.3%, respectively, and the difference showed no significant differences ( P.  = 0.95). Multivariate Cox regression analysis demonstrated that male gender and age ≥50 years are independent risk factors of HCC development (OR = 2.987 and 2.408; 95% CI (1.301–6.858) and (1.126–5.149); P.  = 0.01 and 0.02, respectively). 结论。HBV相关DC患者的HCC风险仍然很高，尤其是≥50岁的男性。SN - 2291-2789 UR - https://doi.org/10.1155/2020/8871024 do - 10.1155 / 2020/8871024 jf - 加拿大胃肠学和肝脏学杂志pb - hindawikw - er -